Zatebradine HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 561430

CAS#: 91940-87-3

Description: Zatebradine HCl is a bradycardic agent. It blocks hyperpolarization-activated inward current (If) through cyclic nucleotide-gated cation (HCN) channels in sinoatrial node cells.

Price and Availability


USD 230

USD 390

USD 730

Zatebradine HCl, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 561430
Name: Zatebradine HCl
CAS#: 91940-87-3
Chemical Formula: C26H37ClN2O5
Exact Mass:
Molecular Weight: 493.04
Elemental Analysis: C, 63.34; H, 7.56; Cl, 7.19; N, 5.68; O, 16.22

Synonym: Zatebradine HCl; Zatebradine Hydrochloride; UL-FS49; UL FS49; ULFS49;

IUPAC/Chemical Name: 3-[3-[2-(3,4-Dimethoxyphenyl)ethyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one hydrochloride


InChi Code: InChI=1S/C26H36N2O5.ClH/c1-27(13-9-19-7-8-22(30-2)23(15-19)31-3)11-6-12-28-14-10-20-16-24(32-4)25(33-5)17-21(20)18-26(28)29;/h7-8,15-17H,6,9-14,18H2,1-5H3;1H


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Bois P, Guinamard R, Chemaly AE, Faivre JF, Bescond J. Molecular regulation and pharmacology of pacemaker channels. Curr Pharm Des. 2007;13(23):2338-49. Review. PubMed PMID: 17692005.

2: Schipke JD, Büter I, Hohlfeld T, Schmitz-Spanke S, Gams E. [Selective I(f) channel inhibition: an alternative for treating coronary artery disease?]. Herz. 2006 Feb;31(1):55-74. Review. German. PubMed PMID: 16502273.

3: Cerbai E, Mugelli A. [The pacemaker current If: a novel pharmacological target for cardiologists]. Ital Heart J Suppl. 2005 Jul;6(7):413-9. Review. Italian. PubMed PMID: 16082824.

4: Berdeaux A, Colin P, Monnet X, Ghaleh B. [Heart rate and experimental myocardial ischaemia]. Therapie. 2004 Sep-Oct;59(5):507-10. Review. French. PubMed PMID: 15648302.

5: Yusuf S, Camm AJ. Sinus tachyarrhythmias and the specific bradycardic agents: a marriage made in heaven? J Cardiovasc Pharmacol Ther. 2003 Jun;8(2):89-105. Review. PubMed PMID: 12808482.

6: De Clerck F, Van de Water A, D'Aubioul J, Lu HR, van Rossem K, Hermans A, Van Ammel K. In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: application to the preclinical cardiovascular safety pharmacology of a new chemical entity. Fundam Clin Pharmacol. 2002 Apr;16(2):125-40. Review. PubMed PMID: 12031065.

7: Schipke JD, Harasawa Y, Sugiura S, Alexander J Jr, Burkhoff D. Effect of a bradycardic agent on the isolated blood-perfused canine heart. Cardiovasc Drugs Ther. 1991 Apr;5(2):481-8. Review. PubMed PMID: 1854656.

8: Kobinger W, Lillie C. Specific bradycardic agents--a novel pharmacological class? Eur Heart J. 1987 Dec;8 Suppl L:7-15. Review. PubMed PMID: 2897916.